Scientists for the first time have used CRISPR gene editing to halt the progression of Duchenne muscular dystrophy (DMD) in a large mammal, according to a study by UT Southwestern that provides a strong indication that a lifesaving treatment may be in the pipeline.
The research published in Science documents unprecedented improvement in the muscle fibers of dogs with DMD – the most common fatal genetic disease in children, caused by a mutation that inhibits the production of dystrophin, a protein critical for muscle function.
Researchers used a single-cut gene-editing technique to restore dystrophin in muscle and heart tissue by up to 92 percent of normal levels. Scientists have estimated a 15 percent threshold is needed to significantly help patients.
“Children with DMD often die either because their heart loses the strength to pump, or their diaphragm becomes too weak to breathe,” said Dr. Eric Olson, Director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine. “This encouraging level of dystrophin expression would hopefully prevent that from happening.”
DMD, which affects one in 5,000 boys, leads to muscle and heart failure, and premature death by the early 30s. Patients are forced into wheelchairs as their muscles degenerate and eventually onto respirators as their diaphragms weaken. No effective treatment exists, though scientists have known for decades that a defect in the dystrophingene causes the condition.
The Science study establishes the proof-of-concept for single-cut gene editing in dystrophic muscle and represents a major step toward a clinical trial. Already Dr. Olson’s team has corrected DMD mutations in mice and human cells by making single cuts at strategic points of the mutated DNA.
The latest research applied the same technique in four dogs that shared the type of mutation most commonly seen in DMD patients. Scientists used a harmless virus called adeno-associated virus (AAV) to deliver CRISPR gene-editing components to exon 51, one of the 79 exons that comprise the dystrophin gene.
CRISPR edited the exon, and within several weeks the missing protein was restored in muscle tissue throughout the body, including 92 percent correction in the heart and 58 percent in the diaphragm, the main muscle needed for breathing.
“Our strategy is different from other therapeutic approaches for DMD because it edits the mutation that causes the disease and restores normal expression of the repaired dystrophin,” said Dr. Leonela Amoasii, lead author of the study and Assistant Instructor of Molecular Biology in Dr. Olson’s lab. “But we have more to do before we can use this clinically.”
The lab will next conduct longer-term studies to measure whether the dystrophin levels remain stable and to ensure the gene edits do not have adverse side effects.
Dr. Olson hopes the next step beyond dogs is a clinical trial, which would be among several that UT Southwestern’s gene therapy center aims to launch in the coming years to address numerous deadly childhood diseases.
In the meantime, Dr. Olson’s recent work has spawned a biotechnology company, Exonics Therapeutics Inc., which is working to further optimize and bring this technology to the clinic. Exonics intends to extend the approach to additional DMD mutations, as well as other neuromuscular diseases. Exonics has licensed the technology from UT Southwestern.
The Latest on: Duchenne muscular dystrophy
[google_news title=”” keyword=”Duchenne muscular dystrophy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Duchenne muscular dystrophy
- Buy Rating Affirmed for Edgewise Therapeutics Amid Anticipated Positive Trial Outcomes and Strategic FDA Alignmenton February 25, 2024 at 8:27 pm
such as Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD), sets a favorable investor expectation. The anticipated data from multiple trials, including Phase 1b, Phase 2, and ...
- 'Funny, caring and charming' Durham lad wins award for looking after brother with muscular dystrophyon February 25, 2024 at 10:01 am
William Jackson, 16, received a President's Award from charity Muscular Dystrophy UK in honour of caring for his brother Louis - who is 12 and has Duchenne muscular dystrophy. William, who is a pupil ...
- Strength Training Safely Boosts Muscular Dystrophy Outcomes, but Further Study Neededon February 21, 2024 at 4:00 pm
Their review demonstrated the positive impact that trunk-oriented strength exercises can have when added to usual care, vs usual care alone, for children whose MD diagnosis is Duchenne muscular ...
- Parent Project Muscular Dystrophy Announces Pediatric Certified Duchenne Care Center, Penn State Health Children's Hospitalon February 21, 2024 at 7:01 am
Leading Duchenne Organization Expands Certification of Clinics that Provide Optimal Care for People with Duchenne Muscular Dystrophy with Addition of Clinic in Eastern Pennsylvania WASHINGTON, Feb ...
- Herpes-Dementia Link; How COVID Affects the Brain; FDA to Decide on Duchenne Drugon February 20, 2024 at 11:54 am
German researchers showed that SARS-CoV-2 did not persist in brain cells and supported the idea that COVID's neurologic complications may be due to inflammatory immune reactions. ( Nature Neuroscience ...
- Novel ASO screening study paves the way for duchenne muscular dystrophy (DMD) therapy advancementson February 20, 2024 at 2:11 am
This article talks about the identification of a novel ASO (AON-C19) which opens a promising new avenue for Duchenne Muscular Dystrophy (DMD) therapy development.
- Santhera’s Duchenne muscular dystrophy drug shows promise as long-term treatmenton February 18, 2024 at 4:00 pm
Santhera Pharmaceuticals has announced the publication of results in the journal Neurology that support the long-term efficacy and safety profile of its Duchenne muscular dystrophy (DMD) drug, Agamree ...
- FDA to review expanded use of Sarepta Duchenne gene therapyon February 16, 2024 at 3:55 am
The Food and Drug Administration will decide by June 21 whether to loosen the restrictions surrounding use of Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy, the company said ...
- FDA grants fast track status to Edgewise’s Duchenne treatmenton February 14, 2024 at 4:29 am
The designation expedites the development and review of EDG-5506, an oral small molecule for the prevention of contraction-induced muscle damage.
- Duchenne Muscular Dystrophy Market Size Predicted To Hit USD 2.1 Billion By 2031 At 4.7% CAGR, Says AMRon February 13, 2024 at 10:33 pm
Duchenne Muscular Dystrophy Market 2024 Rise in the incidence of the Duchenne muscular dystrophy (DMD) and surge in need for better healt ...
via Bing News